for patients with multiple architectural distortion (AD) identified on digital breast tomosynthesis (DBT), biopsy of all areas may be warranted, given the variation of pathologic diagnoses across AD in individual patients

72-year-old woman recalled from screening mammography for architectural distortion in left breast. A. Craniocaudal and B. mediolateral oblique digital breast tomosynthesis images demonstrate two areas of AD in upper outer left breast (circles) that persisted on additional diagnostic tomosynthesis images (not shown). C. Transverse greyscale ultrasound image of upper outer breast shows irregular hypoechoic mass with associated AD at 12:30 (arrow), corresponding to posterior AD. No ultrasound correlate was identified for anterior AD. Ultrasound-guided biopsy of posterior AD revealed malignancy (invasive lobular carcinoma). Tomosynthesis-guided biopsy of anterior AD yielded benign pathology (stromal fibrosis). 


July 28, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), for patients with multiple architectural distortion (AD) identified on digital breast tomosynthesis (DBT), biopsy of all areas may be warranted, given the variation of pathologic diagnoses across AD in individual patients. 

“Multiple AD, compared with single AD, was significantly more likely to yield high-risk pathology, but there was no significant difference in yield of malignancy,” wrote corresponding author Lilian C. Wang, MD, of Northwestern Medicine. “In patients with multiple AD, multiple ipsilateral or contralateral AD commonly varied in pathologic classification: benign, high risk, or malignant.” 

Wang and colleagues’ retrospective study included 402 patients (mean age, 56 years) who underwent image-guided core needle biopsy of AD visualized on DBT between April 7, 2017, and April 16, 2019. Patients were grouped in the single or multiple AD cohort based on the presence of distinct AD areas noted in the clinical report, while the pathologic diagnosis for each AD was based on the most aggressive pathology identified on either biopsy or surgical excision (if performed). 

Ultimately, compared with single AD, multiple AD showed a higher frequency of high-risk pathology (53.0% vs. 32.5%, p=.002) but no significantly different frequency of malignancy on a per-lesion or per-patient basis (31.8% vs. 28.2%, p=.56). In 8/24 patients with ≥2 ipsilateral biopsied AD, the ipsilateral areas varied in terms of most aggressive pathology; in 5/10 patients with contralateral biopsied AD, the contralateral areas varied in most aggressive pathology.  

“To our knowledge,” the authors of this AJR article contended, “this is the first study to compare pathologic outcomes between patients with single and multiple AD visualized by DBT.” 

For more information: www.arrs.org 

Related Digital Breast Tomosynthesis Content: 

Today's Mammography Advancements 

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings 

AI DBT Impact on Mammography Post-breast Therapy 

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI 

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs 

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography


Related Content

News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
Subscribe Now